Presentation is loading. Please wait.

Presentation is loading. Please wait.

Graph showing the annual registration count of trials where HER2-directed agents have been, or are being, tested in HER2 mutant cancers. Graph showing.

Published byἸωσίας Αβραμίδης Modified over 5 years ago

Similar presentations

Presentation on theme: "Graph showing the annual registration count of trials where HER2-directed agents have been, or are being, tested in HER2 mutant cancers. Graph showing."— Presentation transcript:

1 Graph showing the annual registration count of trials where HER2-directed agents have been, or are being, tested in HER2 mutant cancers. Graph showing the annual registration count of trials where HER2-directed agents have been, or are being, tested in HER2 mutant cancers. Trials registered by 13 August 2017 on the US National Institutes of Health (NIH) trial registry were categorised according to year of registration and targeted cancer type. All trials have been included, including one trial withdrawn prior to enrolment and one trial terminated due to insufficient accrual. GFR, growth factor receptor; TMD, transmembrane domain. Claire M Connell, and Gary J Doherty ESMO Open 2017;2:e000279 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Graph showing the annual registration count of trials where HER2-directed agents have been, or are being, tested in HER2 mutant cancers. Graph showing."

Similar presentations

From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2013;159(10):698-708.

From: Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2013;159(10):
(A) Schematic diagrams demonstrating the HER2 mutational heterogeneity among and between cases of invasive breast cancer (n=963), bladder urothelial cancer.

(A) Schematic diagrams demonstrating the HER2 mutational heterogeneity among and between cases of invasive breast cancer (n=963), bladder urothelial cancer.
(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.
A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,
Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA.

Plots derived from provisional TCGA data from sequencing and expression analyses of invasive breast carcinoma cases. Plots derived from provisional TCGA.
(A) Graph showing the changes in liver function tests over time for case 1, with a summary of systemic treatments given over time. (A) Graph showing the.

(A) Graph showing the changes in liver function tests over time for case 1, with a summary of systemic treatments given over time. (A) Graph showing the.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
The decision tree with the two alternatives.

The decision tree with the two alternatives.
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
Detection rate for EGFR mutations in cfDNA.

Detection rate for EGFR mutations in cfDNA.

Similar presentations

Ads by Google